Chemomab Therapeutics Ltd. (CMMB)
NASDAQ: CMMB · Real-Time Price · USD
1.160
0.00 (0.00%)
Apr 22, 2025, 11:11 AM EDT - Market open
Company Description
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases in the United States.
Its lead product candidate is CM-101, a humanized monoclonal antibody attenuates the basic function of CCL24 that is in phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).
Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.
Chemomab Therapeutics Ltd.
| Country | Israel |
| Founded | 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 20 |
| CEO | Adi George |
Contact Details
Address: Building 7, Kiryat Atidim Tel Aviv, 6158002 Israel | |
| Phone | 972 77 331 0156 |
| Website | chemomab.com |
Stock Details
| Ticker Symbol | CMMB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001534248 |
| CUSIP Number | 03280X102 |
| ISIN Number | US16385C1045 |
| Employer ID | 81-3676773 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Adi Mor George Ph.D. | Co-Founder, Chief Scientific Officer, Chief Executive Officer and Executive Director |
| Sigal Fattal CPA, M.B.A. | Chief Financial Officer |
| Dr. Matthew B. Frankel M.B.A., M.D. | Chief Medical Officer and Vice President of Drug Development |
| Barbara Lindheim | Consulting Vice President of Investor and Public Relations, Strategic Communications |
| Dr. David M. Weiner M.D. | Interim Chief Medical Officer |
| Jack Lawler | Chief Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 15, 2025 | 6-K | Report of foreign issuer |
| Apr 10, 2025 | SCHEDULE 13G/A | Filing |
| Apr 4, 2025 | 20-F | Annual and transition report of foreign private issuers |
| Mar 27, 2025 | 6-K | Report of foreign issuer |
| Mar 20, 2025 | 6-K | Report of foreign issuer |
| Mar 3, 2025 | 6-K | Report of foreign issuer |
| Feb 19, 2025 | 6-K | Report of foreign issuer |
| Dec 10, 2024 | EFFECT | Notice of Effectiveness |
| Dec 2, 2024 | POS AM | Post-Effective amendments for registration statement |
| Nov 29, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |